Literature DB >> 9412888

Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.

H P Grocott1, J Root, S D Berkowitz, N deBruijn, K Landolfo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9412888     DOI： 10.1016/s1053-0770(97)90124-5

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN： 1053-0770            Impact factor:   2.628


× No keyword cloud information.
  4 in total

Review 1.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

3.  Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation.

Authors:  Yoshinori Tanigawa; Tomoko Yamada; Koichi Matsumoto; Akira Nakagawachi; Arisu Torikai; Yoshirou Sakaguchi
Journal:  J Anesth       Date:  2013-05-16       Impact factor: 2.078

4.  Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.

Authors:  Rebecca L Morgan; Vahid Ashoorion; Adam Cuker; Housne Begum; Stephanie Ross; Nina Martinez; Beng H Chong; Lori A Linkins; Theodore E Warkentin; Wojtek Wiercioch; Robby Nieuwlaat; Holger Schünemann; Nancy Santesso
Journal:  Blood Adv       Date:  2020-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.